Prothena’s PRX012 Trial Begins Dosing Patients, Healthy Volunteers

Prothena has begun testing single ascending doses (SAD) of PRX012, its investigational anti-amyloid beta antibody therapy, in a Phase 1 clinical trial with healthy volunteers and people with Alzheimer’s disease. This follows the recent approval of the company’s investigational new drug (IND) application for PRX012 by the U.S. Food and Drug Administration. A next-generation antibody, PRX012 is meant to bind to toxic forms of amyloid beta that underlie Alzheimer’s disease. This means the therapy may…

You must be logged in to read/download the full post.